Edition:
India

Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

62.82USD
18 Jun 2018
Change (% chg)

-- (--)
Prev Close
$62.82
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,740,304
52-wk High
$64.60
52-wk Low
$47.83

Select another date:

Thu, Jun 14 2018

Allergan appoints former Abbott executive to its board

June 14 Allergan Plc said on Thursday former Abbott Laboratories executive Thomas Freyman will join its board, a week after two of its shareholders criticized the drugmaker's acquisition strategy and board composition.

BRIEF-Abbott Expands Cardiac Arrhythmias Portfolio With FDA Clearance Of Advanced Mapping Catheter

* ABBOTT EXPANDS CARDIAC ARRHYTHMIAS PORTFOLIO WITH FDA CLEARANCE OF ADVANCED MAPPING CATHETER

BRIEF-Abbott's Xience Sierra Heart Stent Receives National Reimbursement In Japan

* ABBOTT'S XIENCE SIERRA™ HEART STENT RECEIVES NATIONAL REIMBURSEMENT IN JAPAN TO TREAT PEOPLE WITH CORONARY ARTERY DISEASE Source text for Eikon: Further company coverage:

BRIEF-Abbott Laboratories Says Shareholders Rejected Proposal Requesting Board Of Directors Adopt Policy That Board Chairman Be Independent Director

* ABBOTT LABORATORIES SAYS SHAREHOLDERS REJECTED PROPOSAL REQUESTING CO'S BOARD OF DIRECTORS ADOPT POLICY THAT BOARD CHAIRMAN BE INDEPENDENT DIRECTOR Source text: (https://bit.ly/2KqCwQY) Further company coverage:

BRIEF-Abbott Laboratories - Co, Sanquin Sign Multiple-Year Contract For Supply Of Primary Serological Equipment And Consumables

* ABBOTT LABORATORIES - CO, SANQUIN SIGN MULTIPLE-YEAR CONTRACT FOR SUPPLY OF PRIMARY SEROLOGICAL EQUIPMENT AND CONSUMABLES Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

Abbott sticks to earlier forecasts, disappoints investors

Abbott Laboratories' just beat expectations for first quarter profits and revenue on Wednesday but stuck to a full-year profit forecast some investors had expected would be raised, sending the healthcare company's shares lower.

Abbott sticks to earlier forecasts, disappoints investors

Abbott Laboratories' just beat expectations for first quarter profits and revenue on Wednesday but stuck to a full-year profit forecast some investors had expected would be raised, sending the healthcare company's shares lower.

UPDATE 3-Abbott sticks to earlier forecasts, disappoints investors

* Analysts cite disappointment on whisper numbers among investors

BRIEF-Abbott Q1 GAAP Earnings Per Share $0.23 From Continuing Operations

* Q1 GAAP EARNINGS PER SHARE $0.23 FROM CONTINUING OPERATIONS

Abbott Labs' quarterly revenue rises 16.7 percent

April 18 Abbott Laboratories on Wednesday posted a 16.7 percent rise in quarterly revenue, helped by strong demand for its newer devices.

Select another date: